HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT07233070

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07233070
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07233070. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-31 (actual); primary completion 2026-09-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.
Condition
Acute Ischemic Stroke
Intervention (Drug)
HRS-7450 Injection
Intervention (Drug)
HRS-7450 Injection
Intervention (Drug)
HRS-7450 Injection
Intervention (Drug)
HRS-7450 Injection Placebo
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07233070
Content hash
a557166b9b541ea57879ee83a6aee09c7b04868d138832aba36b7c7b8472f5b2